630 W GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Preannounces Strong Q3 2025 Wakix Performance; Raises 2025 Revenue Guidance
Provides Update From Its Phase 3 RECONNECT Study Of ZYN002 In Fragile X Syndrome
Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data from Phase 3 Registrational Trial in Q3 2025
Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025
STRENGTHENS PATENT POSITION WITH FAVORABLE SETTLEMENT IN ANDA LITIGATION
Shareholder votes
Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance
Annual Report to Security Holders
Q2
Q1
FY 2023
Q3
FY 2023 amended
Registration Statement for Securities to be Offered to Employees
S-3ASR
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Prospectus filed pursuant to Rule 424(b)(7)
Amended Tender Offer Statement by Third Party